Opioid use before knee replacement surgery results in worse pain outcomes for patients
Boston, MA– There is growing concern regarding opiod use prior to a total knee replacement (TKR), and recent research has suggested that preoperative opioid use may lead to worse pain outcomes following surgery. A team of investigators at Brigham and Women's Hospital evaluated pain relief associated with TKR in patients who had used opioids before their procedure and compared it to pain relief in patients who had not. The authors found that patients who had higher pain catastrophising, the degree of an exaggerated, negative response to pain, were more likely to take opioids for pain relief. They found that patients who used opioids to manage their knee pain before their total knee replacement had less pain relief after the operation. The study was published in the Journal of Bone and Joint Surgery.
"With these study results, we'd encourage physicians to consider discussing long term implications of opioid therapy with their patients," says Elena Losina, PhD, lead author, director of the Policy and Innovation Evaluation in Orthopedic Treatments Center and co-director of the Orthopedics and Arthritis Center for Outcomes Research at Brigham and Women's Hospital. "Although each patient case is different, patients and physicians should discuss the potential impact of using opioids in patients with knee osteoarthritis who are likely to consider total knee replacement within the next two years."
Knee osteoarthritis is a condition associated with significant activity limitation and chronic pain. While a TKR is an effective treatment in relieving pain and restoring function, patients spend an average of 13 years using non-surgical options for pain management including the use of non-steroidal anti-inflammatory drugs, physical therapy, and intra-articular injections. As the authors quote in the paper, the United States has spent over $1.5 billion annually on prescription opioids for people with knee osteoarthritis. Additionally, opioid utilization has increased drastically, with nearly 40 percent of Medicare patients with knee osteoarthritis receiving at least one opioid prescription in 2009. Although previous studies have suggested that using opiods preoperatively is associated with poor pain outcomes, the research was based on limited sample sizes and pain catastrophizing was not considered.
The team reviewed data from 156 patients who had TKR at an average age of 66. They collected patient-reported outcomes and demographic data both before and six months after surgery, and abstracted data regarding opiod use from the patients' medical records. Researchers found that prior to surgery, 23 percent of patients had at least one opioid prescription.
Using standard pain scales (Pain Catastrophizing Scale, the Western Ontario and the McMaster Universities Osteoarthritis Index (WOMAC)), researchers quantified the pain experiences of patients undergoing TKR. Researchers used sophisticated analytic methods to compare the change in the WOMAC pain score six months after knee surgery and establish the difference between patients who had and those who had not used opioids before TKR. Researchers found that the patients who used opioids prior to surgery had about 9 percent less pain reduction at six months following surgery.
"Our findings support previous research that indicated preoperative opiod use was associated with worse clinical outcomes. This data demonstrates that preoperative opioid use may also lead to lesser pain relief in the early postoperative period," said Losina.
The researchers also note that since the U.S. spends over $1.5 billion annually on prescription opioids for patients with knee osteoarthritis, and nearly $30 billion on illicit use, reducing the use of opioids may decrease their harmful effects. Clinicians and policy makers may consider limiting the use of opioids prior to TKR to optimize post-TKR pain relief.
This research was supported by the National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, Grant K24AR057827 and Partners HealthCare.
Paper cited: Losina et al. "Impact of Preoperative Opioid Use on Total Knee Arthroplasty Outcomes." Journal of Bone and Joint Surgery, DOI: 10.2106/JBJS.16.01200
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 4.2 million annual patient visits and nearly 46,000 inpatient stays, is the largest birthing center in Massachusetts and employs nearly 16,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 3,000 researchers, including physician-investigators and renowned biomedical scientists and faculty supported by nearly $666 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials groups. For more information, resources and to follow us on social media, please visit BWH's online newsroom.
Related Journal Article